Three Pharmaceutical Stocks to Consider Buying to Profit from a Weight-Loss Trend07/07/2026 |
|
1.5M+ users. 70% lighter than the Vision Pro. AI is changing how people work. Professionals are managing more information and projects than ever, across more locations. But they're still using screens that weren't built for it.
1.5M+ people use Immersed to create a virtual workspace with access to up to five monitors from anywhere. The company also built Visor, a headset 70% lighter than Apple Vision Pro at one-third the cost. 75,000+ on the waitlist.
Current Reg A+ offering ends July 30. Invest today.
Disclosure: This is a paid advertisement for Immersed Regulation A+ offering. Please read the offering circular at invest.immersed.com Click Here... |
|
|
Three pharmaceutical stocks to consider buying to profit from a weight-loss trend highlight early-stage companies that are overshadowed by the need for further research and head starts by industry frontrunners.
The three pharmaceutical stocks to consider buying to profit from a weight-loss trend are rated as "outperform" by the Chicago-based investment firm William Blair & Co. But they still are engaged in clinical trials without a certain path to profitability.
Research and development (R&D) of pharmaceuticals is not for the timid, especially when nausea is a dreaded side effect of many treatments. Nonetheless, William Blair & Co. wrote that the three companies each have potential.
Three Pharmaceutical Stocks to Consider Buying to Profit from a Weight-Loss Trend: Fink's Forecast
Jim Fink is a seasoned investment professional who is tracking the weight-loss pharmaceutical sector closely. Fink, who leads the Seasonal Stock Alert, Velocity Trader, Options for Income and Inner Circle services, spoke realistically about the need for additional research to overcome significant side effects.
"I'm overweight," Fink said. "Not 'cheat day' overweight -- real, doc-raises-an-eyebrow overweight. I've eyed these drugs the way a man eyes a lifeboat. But two things have kept me on the Titanic: the prohibitive cost, and the fact that half the folks I know on these drugs say their gut feels like a war zone."
Nausea is not a "stellar selling proposition," Fink conceded. But hope and research and development for enhanced products remains.
Three Pharmaceutical Stocks to Consider Buying to Profit from a Weight-Loss Trend: AARD
San Diego, California-based Aardvark Therapeutics (NASDAQ: AARD) is a clinical-stage biopharmaceutical company developing novel, small-molecule therapies designed to inhibit hunger and treat metabolic diseases. The company is seeking to alleviate hunger to treat metabolic diseases and to deliver transformative outcomes for patients.
Hunger and appetite are distinct neurologic drives that affect a person’s response to food consumption. Appetite reflects a desire for reward or pleasure, whereas hunger is driven by the need to avoid pain and discomfort, according to the company.
Although these perceptions interact neurologically in complementary ways, they remain unique and distinguishable processes, Aardvark indicated. The company’s key compound, ARD-101, is an oral investigational drug under development to treat hunger-associated rare diseases. ARD-101 is primarily limited to the digestive tract, where it activates bitter taste receptors (TAS2Rs) to trigger the local release of satiety hormones to activate gut-brain signals that suppress hunger.
Aardvark became a publicly traded company on February 13, 2025, raising approximately $94.2 million through its initial public offering (IPO) of common stock. After initial market gains, Aardvark shares fell following a clinical pause and clinical hold on its lead drug candidate, ARD-101. |
|
My “Backdoor” for the Next Trillion-Dollar IPO Everyone wants to know which major company will go public next. Anthropic? OpenAI? Databricks? I don’t need to guess — because I already own stakes in all of them.
You read that right: I have early, pre-IPO shares of the companies everyone wants. And you can, too. A similar backdoor pre-IPO play got me into SpaceX before its $2 trillion debut…
And now it could help you get in front of the next wave of private-market leaders before the IPO rush begins.
Let me show you how to get positioned while there’s still time. Click Here... |
|
|
Three Pharmaceutical Stocks to Consider Buying to Profit from a Weight-Loss Trend: ARD-101
The company’s lead compound, ARD-101, is an oral investigational drug under development to treat hunger-associated rare diseases. ARD-101 is primarily limited to the digestive tract, where it activates bitter taste receptors (TAS2Rs) to trigger the local release of satiety hormones to activate gut-brain signals that suppress hunger.
The latest financial information available in the first quarter ended March 31, indicated the company has been working closely with the Food and Drug Administration (FDA). Aardvark is trying to evaluate data following reversible cardiac observations in a healthy volunteer trial to assess the best path forward for its programs and patients, said Tien Lee, M.D., founder and chief executive officer of Aardvark.
The company is seeking a path forward for its Phase 3 HERO trial evaluating ARD-101. The reality is that Aardvark Therapeutics is in the development stage and is losing money while it remains in a clinical research phase. It reported a net loss of $21.6 million for the first quarter of 2026, more than double its net loss of $9.3 million for the first quarter of 2025. Despite the outperform rating of William Blair, the company looks like one to watch right now for a possible upturn as a potential future buy.
Chart courtesy of www.stockcharts.com.
Three Pharmaceutical Stocks to Consider Buying to Profit from a Weight-Loss Trend: KLRA
Kailera Therapeutics, Inc (NASDAQ: KLRA), of Waltham, Massachusetts, is a clinical-stage biotechnology company specializes in developing GLP-1 therapies for obesity management. The company is developing therapies for obesity to give people the power to restore their health and transform their lives.
Part of its mission is to develop therapies for obesity to give people the power to restore their health and transform their lives. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. With such a huge target market, obesity is accompanied by more than 200 comorbidities, company officials indicated.
Kailera Therapeutics is pursing the delivery of leading obesity management medications. With experience in developing and commercializing therapies for metabolic diseases, Kailera’s leadership team is intending to efficiently and effectively advance its product pipeline.
Obesity has become one of the most pressing current health challenges, said Kailera Therapeutics' President and Chief Executive Officer Ron Renaud. While the approvals of GLP-1-based obesity management medications have changed the landscape of obesity management, there remains a critical need for medications offering greater weight loss, especially for those living with a higher body mass index (BMI), he added.
Kailera’s lead product candidate, ribupatide, also known as KAI-9531, is in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist that has the potential for the greatest weight loss. In addition, Kailera is expanding the ribupatide franchise by developing a once-daily oral tablet formulation with the goal of providing an oral option with the potential for compelling weight loss and highly differentiated tolerability.
Chart courtesy of www.stockcharts.com. |
|
Are You Sabotaging Your Trading? Don't trade off hope. Don't trade off optimism. Those are not strategies. They are the quiet ways traders sabotage their own accounts.
The most powerful indicator? VantagePoint Artificial Intelligence.
Attend our FREE live training online and our expert will show you what Stocks and Options are setting up for big changes, and how you can better time your entries and exits.
This is a complimentary live class. There are no replays.
Register here. Click Here... |
|
|
Three Pharmaceutical Stocks to Consider Buying to Profit from a Weight-Loss Trend: SKYE
Skye Bioscience, Inc. (NASDAQ: SKYE), a San Diego, California-based therapeutics company endured an experimental treatment failure in October 2025 that sent its share price down more than 60% in a day when it did not achieve its main goal of significantly reducing weight in adults with obesity in a mid-stage study. Such a setback is not catastrophic for companies that have financial backing to persevere but investors need to be aware of the challenges.
William Blair reported that Skye recently provided a recap of its Phase IIa CBeyond trial of nimacimab, a peripherally restricted CB1 receptor inverse agonist antibody, in patients with obesity. The extension portion of the Phase IIa CBeyond study enrolled a total of 19 patients, with 10 patients in the nimacimab plus Wegovy cohort, and nine patients in the Wegovy monotherapy cohort.
In addition, 22 patients did not participate in the extension but were evaluated for weight regain over 12 weeks following prior therapy with Wegovy, or a combination of Wegovy plus nimacimab. Following 12 weeks off-treatment, weight regain for patients on prior Wegovy was 37% versus 18% with the nimacimab combination, the company reported.
Continued treatment resulted in a deepening of responses, with combination therapy achieving up to 23% -- representing 8.3% additional weight loss from the extension -- total weight loss at 52 weeks, versus 20%, representing 5.8% additional, with Wegovy monotherapy, William Blair wrote in a recent research note. Management highlighted the patients in the Wegovy monotherapy arm as representing a subset of high responders to Wegovy, according to their magnitude of weight loss, further underscoring the benefit of adding even low-dose nimacimab, William Blair added.
For the fourth-quarter update, William Blair wrote that it is looking forward to results from the part C expansion study assessing safety and exposure. Further R&D remains ahead.
Chart courtesy of www.stockcharts.com.
Three Pharmaceutical Stocks to Consider Buying to Profit from a Weight-Loss Trend: Geopolitical Risk
With military action taking place and global geopolitical risk a big concern, these three investments offer a potentially profitable path forward amid the chaos. |
|
Sincerely,
Paul Dykewicz, Editor
StockInvestor.com
|
|
About Paul Dykewicz:Paul Dykewicz is an accomplished, award-winning journalist who has written for Dow Jones, the Wall Street Journal, Investor’s Business Daily, USA Today, Seeking Alpha, GuruFocus and other publications and websites. Paul is the editor of StockInvestor.com and DividendInvestor.com, a writer for both websites and a columnist. He further is the editorial director of Eagle Financial Publications in Washington, D.C., where he edits monthly investment newsletters, time-sensitive trading alerts, free e-letters and other investment reports. Paul also is the author of an inspirational book, "Holy Smokes! Golden Guidance from Notre Dame's Championship Chaplain", with a foreword by former national championship-winning football coach Lou Holtz. Follow Paul on Twitter @PaulDykewicz. |
|
|
|
|
|
Visit our YouTube Channel - Eagle Investing Network
Tidak ada komentar:
Posting Komentar